Member Info for Soupdragon78

NFT, can you tell me what happens when they do durability testing?

NFT, the NXP002 testing starts in august and will take a few months. The peer review that is being presented at the ERS has already happened as it was submitted last December.

The difficulty now is how to retain those who recently bought.
My concern is that there will be a lot of small time traders who bought in the past day or so who will likely be looking to exit.

Unless JG and DG can attract some longer term interest then it’ll be a rocky road to any higher valuation.

Finally getting their act together.

Would like to see this first get back to where it was when Anne took over. Then move on to be on a par with Oxilio valuation.

Currently two MM's sat laughably low on the bid. JBER haven't changed at all since open and SCAP hilariously want you to sell of 0.375p and have a 42% spread!

Jokers.

I’d like to think we should hear something soon on how Oxilio have been getting on developing since their deal with Quotient.
They were aiming for phase 1 in the second half of this year giving milestone payments to NFX.

“The Group aims to execute licensing deals early in the development process in order to generate revenue to support the business.”

“The Directors have prepared cash flow forecasts covering the period ending 31 March 2024 that take into account the likely run rate on overheads and research and development expenditure and the prudent expectations of income from out-licensing rights to its programmes.”

Also good to see the Julian and Maddys options only last till end of January next year.

Whilst they aren’t huge quantities it all adds to the boards interest to drive success

Gooding now a director and Julian Non-Exec chairman.

Hopefully satisfactory Jiving?

Didn't last long filter.

I guess the famous 1 trade didn't work this time. Lol!

:-o

Ganners, in terms of sale of company or assets, yes I'd like to think there would be a reasonable price achieved. Escpecially given JH and DG's shareholding, I would like to think they would be keen for a figure to make all their historic efforts worthwhile.

As always its down to what a potential purchaser is willing to pay.

Julian must be having a snooze before the results.

Indeed filter, fully expecting a comment in the full years soon about the board situation and strategy. I doubt they will talk about the plans for selling the company if that was the case. All imho.

In terms of board appointments, I'm leaning more towards the side that they won't be making any at all. They would more than likely have done so by now if this was going to be the case.
Furthermore, it feels more likely that they are looking to sell the assets or company then the major shareholders can walk away with a sum of money. Any outlicensing would see the licensee undertaking the work, so there would be no role for a new CEO to undertake.

Jiving, given the nature of what Therapeutaix do and that the people involved don't hold board positions anywhere else I do not see it as likely they would join the BoD at NFX

Two poster sessions now at the ERS for NXP002.

Simon Cruwys presenting
'In vitro and ex-vivo evaluation of anti-inflammatory and anti-fibrotic effects of NXP002 in rat and human cells and lung tissue'

and Bob Humphries presenting
'Inhaled NXP002 attenuates LPS-induced inflammatory and fibrotic mediator production in the rat lung'

Trying to figure out how long in-vitro dissolution testing is likely to take. We know a month ago they have started the next phase for NXP004 with a scale up of production for the lead cocrystals, which would hopefully only take a few weeks (to my simple brain)
Dissolution testing is seems to be across periods measured in minutes rather than days or weeks, so hopefully could be fairly rapid before we know more about them moving toward formulation.

Some flump on twits reckons they've got 2.5m cash! lol!
If thats not an attempt at p&d then don't know what is.